Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00083889
Registration number
NCT00083889
Ethics application status
Date submitted
3/06/2004
Date registered
4/06/2004
Date last updated
26/01/2010
Titles & IDs
Public title
SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
Query!
Scientific title
A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
Query!
Secondary ID [1]
0
0
A6181034
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Carcinoma, Renal Cell
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Non melanoma skin cancer
Query!
Cancer
0
0
0
0
Query!
Kidney
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Interferon-alfa
Treatment: Drugs - SU011248
Active Comparator: 2 -
Experimental: 1 -
Treatment: Drugs: Interferon-alfa
3 MIU first week, 6 MIU second week, and 9 MIU thereafter three times a week (non-consecutive days) until progression or unacceptable toxicity
Treatment: Drugs: SU011248
50 mg orally daily for 4 weeks and 2 weeks off treatment until progression or unacceptable toxicity
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-Free Survival (PFS), Core Radiology Assessment
Query!
Assessment method [1]
0
0
Progression-free survival (PFS) = time from randomization to first documentation of objective tumor progression or to death due to any cause, whichever occured first. If tumor progression data included more than 1 date, the first date was used. PFS = first event date minus the date of randomization + 1. On study included treatment plus 28-day follow-up periods.
Query!
Timepoint [1]
0
0
Day 28 of each 6-week cycle: duration of treatment phase
Query!
Primary outcome [2]
0
0
Progression-Free Survival (PFS), Investigator's Assessment
Query!
Assessment method [2]
0
0
Progression-free survival = time from randomization to first documentation of objective tumor progression or to death due to any cause, whichever occured first. PFS = first event date minus the date of randomization + 1). On study included treatment plus 28-day follow-up periods.
Query!
Timepoint [2]
0
0
Day 28 of each 6-week cycle: duration of treatment phase
Query!
Secondary outcome [1]
0
0
Objective Response, Core Radiology Assessment
Query!
Assessment method [1]
0
0
Objective response (OR) = the number of patients with confirmed complete response (CR) and confirmed partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, relative to all randomized patients. CR was defined as the disappearance of all target lesions. PR was defined as a = 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Confirmed responses (CR or PR) = those that persisted on repeat imaging study >= 4 weeks after initial documentation of response.
Query!
Timepoint [1]
0
0
Day 28 of each 6-week cycle: duration of treatment phase
Query!
Secondary outcome [2]
0
0
Objective Response, Investigator's Assessment
Query!
Assessment method [2]
0
0
Objective response (OR) = the number of patients with confirmed complete response (CR) and confirmed partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, relative to all randomized patients. CR was defined as the disappearance of all target lesions. PR was defined as a = 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Confirmed responses = those that persist on repeat imaging study >= 4 weeks after initial documentation of response.
Query!
Timepoint [2]
0
0
Day 28 of each 6-week cycle: duration of treatment phase
Query!
Secondary outcome [3]
0
0
Overall Survival (OS)
Query!
Assessment method [3]
0
0
Overall survival (OS) = time from date of randomization to date of death due to any cause. For patients not expiring, survival time was censored at the last date they were known to be alive. Patients lacking data beyond randomization had their survival times censored at the date of randomization with a duration of 1 day.
Query!
Timepoint [3]
0
0
Clinic visit or telephone contact every 2 months until death
Query!
Secondary outcome [4]
0
0
Time to Tumor Progression (TTP), Core Radiology Assessment
Query!
Assessment method [4]
0
0
TTP = time from randomization to first documentation of objective tumor progression. TTP data were censored on the day following the date of last on treatment (including 28 day follow-up period) tumor assessment documenting absence of progressive disease for subjects who did not have objective tumor progression while on treatment or who were given anti-tumor treatment other than study treatment prior to documentation of objective tumor progression. Subjects with no tumor assessments after randomization had TTP censored on the date of randomization with a duration of 1 day.
Query!
Timepoint [4]
0
0
Randomization to first documentation of tumor progression: duration of treatment phase
Query!
Secondary outcome [5]
0
0
Time to Tumor Progression (TTP), Investigator's Assessment
Query!
Assessment method [5]
0
0
TTP = time from randomization to first documentation of objective tumor progression. TTP data were censored on the day following the date of last on treatment (including 28 day follow-up period) tumor assessment documenting absence of progressive disease for subjects who did not have objective tumor progression while on treatment or who were given anti-tumor treatment other than the study treatment prior to documentation of objective tumor progression. Subjects with no tumor assessments after randomization had TTP censored on the date of randomization with a duration of 1 day.
Query!
Timepoint [5]
0
0
Randomization to first documentation of tumor progression: duration of treatment phase
Query!
Secondary outcome [6]
0
0
Duration of Response (DR), Core Radiology Assessement
Query!
Assessment method [6]
0
0
Duration of response (DR) = time from the first documentation of objective tumor response to the first documentation of objective tumor progression or to death due to any cause. DR data were censored on the day following the date of the last on treatment (including 28 day follow-up period) tumor assessment documenting absence of progressive disease for subjects without objective tumor progression who did not die due to any cause while on treatment or who were given anti-tumor treatment other than study treatment prior to observing tumor progression.
Query!
Timepoint [6]
0
0
Day 28 of each cycle: duraton of treatment phase
Query!
Secondary outcome [7]
0
0
Duration of Response (DR), Investigator's Assessment
Query!
Assessment method [7]
0
0
Duration of response (DR) = time from the first documentation of objective tumor response to the first documentaion of objective tumor progression or to death due to any cause. DR data were censored on the day following the date of the last on treatment (including 28 day follow-up period) tumor assessment documenting absence of progressive disease for subjects without objective tumor progression who did not die due to any cause while on treatment or who were given anti-tumor treatment other than study treatment prior to observing tumor progression.
Query!
Timepoint [7]
0
0
Day 28 of each cycle: duration of treatment phase
Query!
Secondary outcome [8]
0
0
FACT-Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) Subscale
Query!
Assessment method [8]
0
0
FACT-Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) subscale of the FKSI to measure advanced kidney cancer disease related symptoms. Includes 9 items: lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, and hematuria. Each question was answered on a five-point Likert-type scale ranging from 0 (not at all) to 4 (very much). Score = the sum score of the item scores in the subscale; total range: 0 to 36. A score greater than 0 indicates the difference favored sunitinib.
Query!
Timepoint [8]
0
0
Day 1 & 28 of each cycle: duration of treatment phase
Query!
Secondary outcome [9]
0
0
FACT-Kidney Symptom Index (FKSI) Subscale
Query!
Assessment method [9]
0
0
FACT-Kidney Symptom Index (FKSI) subscale designed to be a stand-alone instrument to measure symptoms and quality of life in patients with advanced kidney cancer. Contains 15 questions; some questions overlap with the FACT-G questions. Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Total FKSI score = sum score of the 15 item scores; total range: 0 - 60; 0 (most severe symptoms and concerns) to 60 (no symptoms or concerns).
Query!
Timepoint [9]
0
0
Day 1 & 28 of each cycle: duration of treatment phase
Query!
Secondary outcome [10]
0
0
Functional Assessment of Cancer Therapy-General (FACT-G)
Query!
Assessment method [10]
0
0
Functional Assessment of Cancer Therapy-General (FACT-G): core questionnaire of the Functional Assessment of Chronic Illness Therapy (FACIT) measurement system that has been validated in a variety of cancer populations. 27 questions grouped into 4 domains that measure a patient's physical, functional, social and family, and emotional well-being. Five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = sum score of item scores in the subscale; total range: 0 to 108 with higher score indicating better quality of life.
Query!
Timepoint [10]
0
0
Day 1 & 28 of each cycle: duration of treatment phase
Query!
Secondary outcome [11]
0
0
Functional Assessment of Cancer Therapy-General (FACT-G): Physical Well Being (PWB) Subscale
Query!
Assessment method [11]
0
0
Physical well-being (PWB) subscale of the Functional Assessment of Cancer Therapy-General (FACT-G). Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = the sum score of the item scores in the subscale; range: 0 to 28; lower score indicates better physical well-being.
Query!
Timepoint [11]
0
0
Day 1 & 28 of each cycle: duration of treatment phase
Query!
Secondary outcome [12]
0
0
Functional Assessment of Cancer Therapy-General (FACT-G): Social/Family Well Being (SWB) Subscale
Query!
Assessment method [12]
0
0
Social/family well-being (SWB)subscale of the Functional Assessment of Cancer Therapy-General (FACT-G). Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = the sum score of the item scores in the subscale; range: 0 to 28; lower score indicates less social/family well-being.
Query!
Timepoint [12]
0
0
Day 1 & 28 of each cycle: duration of treatment phase
Query!
Secondary outcome [13]
0
0
Functional Assessment of Cancer Therapy-General (FACT-G): Emotional Well Being (EWB) Subscale
Query!
Assessment method [13]
0
0
Emotional well-being (EWB)subscale of the Functional Assessment of Cancer Therapy-General (FACT-G). Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = the sum score of the item scores in the subscale; range: 0 to 24; lower score indicates better emotional well-being.
Query!
Timepoint [13]
0
0
Day 1 & 28 of each cycle: duration of treatment phase
Query!
Secondary outcome [14]
0
0
Functional Assessment of Cancer Therapy-General (FACT-G): Functional Well Being (FWB) Subscale
Query!
Assessment method [14]
0
0
Functional well-being (FWB) subscale of the Functional Assessment of Cancer Therapy-General (FACT-G). Each question was answered on a five-point Likert-type scale ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). Score = the sum score of the item scores in the subscale; range: 0 to 28; higher score indicates greater functional well-being.
Query!
Timepoint [14]
0
0
Day 1 & 28 of each cycle: duration of treatment phase
Query!
Secondary outcome [15]
0
0
EuroQoL Five Dimension (EQ-5D) Health State Index
Query!
Assessment method [15]
0
0
EQ-5D Health State Index: a brief, self-administered generic health status instrument. Respondents were asked to describe their current health state on each of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety or depression) on a three-level scale (1=no problem, 2=some problem, and 3=extreme problem). A maximum score of 1 can be derived from these 5 dimensions by score conversion; range: -0.39 (worst health state)to 1.00 (best health state). This descriptive system classifies respondents into one of 243 possible distinct health states (EQ-5D descriptive system).
Query!
Timepoint [15]
0
0
Day 1 & 28 of each cycle: duration of treatment phase
Query!
Secondary outcome [16]
0
0
Euro-QoL Visual Analog Scale (EQ-VAS)
Query!
Assessment method [16]
0
0
EQ-VAS: overall self-rating rating of the patient's current health state using a 20 cm Visual Analog Scale (EQ-VAS), also called the health state thermometer) is a metric measurement (in 2 mm interval) from the visual analog scale which ranges between 0 (worse imaginable health state) and 100 (best imaginable health state).
Query!
Timepoint [16]
0
0
Day 1 & 28 of each cycle: duration of treatment phase
Query!
Secondary outcome [17]
0
0
Plasma Concentrations of Soluble Proteins: Plasma VEGF-A, Plasma VEGF-C, Plasma sVEGFR-3, PLASMA IL-8, and PLASMA bFGF That May be Associated With Tumor Proliferation or Angiogenesis
Query!
Assessment method [17]
0
0
Plasma concentrations of soluble proteins that may be associated with tumor proliferation or angiogenesis collected from a subset of patients were analyzed by enzyme-linked immunosorbent assay (ELISA) analysis. Soluble protein values: Baseline concentration (pM) and ratio to Baseline at each timepoint; ratio = plasma concentration of soluble protein (picograms per milliliter [pg/ml]) at timepoint / concentration of soluble protein (pg/ml) at baseline. Samples below the limit of quantitation and samples with insufficient volume available were excluded.
Query!
Timepoint [17]
0
0
Day 1 & Day 28, Cycle 1 to Cycle 4
Query!
Secondary outcome [18]
0
0
Plasma Concentrations of Soluble Proteins: Plasma Basic Fibroblast Growth Factor (bFGF) That May be Associated With Tumor Proliferation or Angiogenesis
Query!
Assessment method [18]
0
0
Plasma concentrations of soluble proteins that may be associated with tumor proliferation or angiogenesis collected from a subset of patients were analyzed by enzyme-linked immunosorbent assay (ELISA) analysis. Soluble protein values: Baseline concentration (pM) and ratio to Baseline at each timepoint; ratio = plasma concentration of soluble protein (picograms per milliliter [pg/ml]) at timepoint / concentration of soluble protein (pg/ml) at baseline. Samples below the limit of quantitation and samples with insufficient volume available were excluded.
Query!
Timepoint [18]
0
0
Day 1 & Day 28, Cycle 1 to Cycle 4
Query!
Secondary outcome [19]
0
0
Incremental Cost Effectiveness Ratio (ICER)
Query!
Assessment method [19]
0
0
Incremental cost effectiveness ratio (ICER) of sunitinib compared to IFN-a as first-line treatment for MRCC, defined as the ratio of the incremental cost of treatment over the incremental effectiveness; effectiveness measured as quality adjusted life year (QALY) gain. This objective was not addressed in the clinical study report, but an interim analysis of cost-effectiveness was presented separately. These results were not available for inclusion at the time of this posting.
Query!
Timepoint [19]
0
0
post study measurement
Query!
Secondary outcome [20]
0
0
Ctrough Concentrations of SU011248
Query!
Assessment method [20]
0
0
Subject observed Ctrough (trough drug) concentrations of SU011248 per cycle and study day determined by plasma trough samples collected from a subset of patients. Steady-state observed trough concentrations were dose corrected to the starting dose (reference dose) where appropriate. Concentrations below the limits of quantitation (BLQ) were set to 0. Ctrough = minimum (trough) plasma concentration (nanograms per milliliter [ng/mL]).
Query!
Timepoint [20]
0
0
Day 28 of Cycle 1 to Cycle 4
Query!
Secondary outcome [21]
0
0
Ctrough Concentrations of Metabolite SU012662
Query!
Assessment method [21]
0
0
Subject observed Ctrough (trough drug) concentrations of active metabolite SU012662 per cycle and study day determined by plasma trough samples collected from a subset of patients. Steady-state observed trough concentrations were dose corrected to the starting dose (reference dose) where appropriate. Concentrations below the limits of quantitation (BLQ) were set to 0. Ctrough = minimum (trough) plasma concentration (nanograms per milliliter [ng/mL]).
Query!
Timepoint [21]
0
0
Day 28 of Cycle 1 to Cycle 4
Query!
Secondary outcome [22]
0
0
Ctrough Concentrations of SU011248 and Active Metabolite SU012662
Query!
Assessment method [22]
0
0
Subject observed Ctrough (trough drug) concentrations of total drug (SU011248 and its active metabolite SU012662) per cycle and study day determined by plasma trough samples collected from a subset of patients. Steady-state observed trough concentrations were dose corrected to the starting dose (reference dose) where appropriate. Concentrations below the limits of quantitation (BLQ) were set to 0. Ctrough = minimum (trough) plasma concentration (nanograms per milliliter [ng/mL]).
Query!
Timepoint [22]
0
0
Day 28 of Cycle 1 to Cycle 4
Query!
Eligibility
Key inclusion criteria
- Histologically confirmed renal cell carcinoma of clear cell histology with metastases
- Evidence of measurable disease by radiographic technique
- Eastern Cooperative Oncology Group [ECOG] performance status of 0 or 1
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Prior systemic (including adjuvant or neoadjuvant) therapy of any kind for RCC
- History of or known brain metastases
- Serious acute or chronic illness or recent history of significant cardiac abnormality
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/08/2004
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/09/2008
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
750
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Pfizer Investigational Site - Lismore
Query!
Recruitment hospital [2]
0
0
Pfizer Investigational Site - St. Leonards
Query!
Recruitment hospital [3]
0
0
Pfizer Investigational Site - South Brisbane
Query!
Recruitment hospital [4]
0
0
Pfizer Investigational Site - Woodville South
Query!
Recruitment hospital [5]
0
0
Pfizer Investigational Site - East Melbourne
Query!
Recruitment hospital [6]
0
0
Pfizer Investigational Site - Perth
Query!
Recruitment hospital [7]
0
0
Pfizer Investigational Site - Victoria
Query!
Recruitment postcode(s) [1]
0
0
2480 - Lismore
Query!
Recruitment postcode(s) [2]
0
0
2065 - St. Leonards
Query!
Recruitment postcode(s) [3]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [4]
0
0
5011 - Woodville South
Query!
Recruitment postcode(s) [5]
0
0
3002 - East Melbourne
Query!
Recruitment postcode(s) [6]
0
0
6000 - Perth
Query!
Recruitment postcode(s) [7]
0
0
36184 - Victoria
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arkansas
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kansas
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kentucky
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Louisiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Maryland
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Massachusetts
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Michigan
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Minnesota
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Mississippi
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Missouri
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Nebraska
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New Hampshire
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New York
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Ohio
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Oklahoma
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Oregon
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Pennsylvania
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Tennessee
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Texas
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Utah
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Washington
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Wisconsin
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
RJ
Query!
Country [29]
0
0
Brazil
Query!
State/province [29]
0
0
RS
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
Alberta
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
British Columbia
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Ontario
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Quebec
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Cedex 15
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Lyon
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Paris Cedex 13
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Rennes
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Saint Herblain
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Vandoeuvre Les Nancy
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Aachen
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Essen
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Hannover
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Ulm
Query!
Country [44]
0
0
Italy
Query!
State/province [44]
0
0
Modena
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Napoli
Query!
Country [46]
0
0
Italy
Query!
State/province [46]
0
0
Pavia
Query!
Country [47]
0
0
Italy
Query!
State/province [47]
0
0
Roma
Query!
Country [48]
0
0
Poland
Query!
State/province [48]
0
0
Warszawa
Query!
Country [49]
0
0
Poland
Query!
State/province [49]
0
0
Gdansk
Query!
Country [50]
0
0
Poland
Query!
State/province [50]
0
0
Krakow
Query!
Country [51]
0
0
Poland
Query!
State/province [51]
0
0
Lodz
Query!
Country [52]
0
0
Poland
Query!
State/province [52]
0
0
Lublin
Query!
Country [53]
0
0
Poland
Query!
State/province [53]
0
0
Poznan
Query!
Country [54]
0
0
Poland
Query!
State/province [54]
0
0
Wroclaw
Query!
Country [55]
0
0
Russian Federation
Query!
State/province [55]
0
0
Kaluga Region
Query!
Country [56]
0
0
Russian Federation
Query!
State/province [56]
0
0
Chelyabinsk
Query!
Country [57]
0
0
Russian Federation
Query!
State/province [57]
0
0
Moscow
Query!
Country [58]
0
0
Russian Federation
Query!
State/province [58]
0
0
Saint-Petersburg
Query!
Country [59]
0
0
Russian Federation
Query!
State/province [59]
0
0
St. Petersburg
Query!
Country [60]
0
0
Russian Federation
Query!
State/province [60]
0
0
Tomsk
Query!
Country [61]
0
0
Spain
Query!
State/province [61]
0
0
Barcelona
Query!
Country [62]
0
0
Spain
Query!
State/province [62]
0
0
Navarra
Query!
Country [63]
0
0
Spain
Query!
State/province [63]
0
0
Madrid
Query!
Country [64]
0
0
Spain
Query!
State/province [64]
0
0
Sevilla
Query!
Country [65]
0
0
United Kingdom
Query!
State/province [65]
0
0
Cardiff
Query!
Country [66]
0
0
United Kingdom
Query!
State/province [66]
0
0
Lancashire
Query!
Country [67]
0
0
United Kingdom
Query!
State/province [67]
0
0
Middlesex
Query!
Country [68]
0
0
United Kingdom
Query!
State/province [68]
0
0
London
Query!
Country [69]
0
0
United Kingdom
Query!
State/province [69]
0
0
Sutton Surrey
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Pfizer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to test whether SU011248 has activity and is safe compared to
interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00083889
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00083889
Download to PDF